SEC Filings

Show all

Stock Information

: (Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Governance

The Board of Directors of Selecta Biosciences sets high standards for the company’s employees, officers, and directors.
Implicit in this philosophy is the importance of sound corporate governance.

Featured Reports
May 06, 2022
Apr 28, 2021

Press Releases

04 Aug
Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) ( Sobi); DISSOLVE I & II studies remain on track for joint topline data readout in Q1 2023 – – Sarepta extends Option and License agreement in exchange for a $2
01 Aug
Selecta Biosciences to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to
28 Jul
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update
WATERTOWN, Mass. , July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to
06 Jul
Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
WATERTOWN, Mass. , July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to